"I was surprised when they suggested to me that this was the way to go, and I questioned it."
--Albert Bourla, CEO of Pfizer, "kicking off his Big Pharma mea culpa cover-up campaign"
Congratulations, 2SG, and you called it months ago (early March).
Of course, we knew this was coming from the "SPARS" pandemic report.
"The SPARS Pandemic 202…
"I was surprised when they suggested to me that this was the way to go, and I questioned it."
--Albert Bourla, CEO of Pfizer, "kicking off his Big Pharma mea culpa cover-up campaign"
Congratulations, 2SG, and you called it months ago (early March).
Of course, we knew this was coming from the "SPARS" pandemic report.
"The SPARS Pandemic 2025–2028:
A Futuristic Scenario to Facilitate Medical Countermeasure Communication"
"ACKNOWLEDGING LOSS"
CHAPTER EIGHTEEN
At the request of HHS Secretary Nagel, ASPR convened a series of meetings among senior leadership of the federal health agencies to address policy and program changes being implemented as a result of a departmental review of the response to the SPARS pandemic. Among the issues considered were the implications of growing negative public opinion regarding Corovax and the government’s perceived indifference to victims of the public health response to SPARS. One senior health official argued that time and a robust medical monitoring program for vaccine recipients—the components of which were already in place—should be sufficient to determine whether public concern about long-term effects was, in fact, warranted: “We have to wait for the data. People need to understand that fact.”
"I was surprised when they suggested to me that this was the way to go, and I questioned it."
--Albert Bourla, CEO of Pfizer, "kicking off his Big Pharma mea culpa cover-up campaign"
Congratulations, 2SG, and you called it months ago (early March).
Of course, we knew this was coming from the "SPARS" pandemic report.
"The SPARS Pandemic 2025–2028:
A Futuristic Scenario to Facilitate Medical Countermeasure Communication"
"ACKNOWLEDGING LOSS"
CHAPTER EIGHTEEN
At the request of HHS Secretary Nagel, ASPR convened a series of meetings among senior leadership of the federal health agencies to address policy and program changes being implemented as a result of a departmental review of the response to the SPARS pandemic. Among the issues considered were the implications of growing negative public opinion regarding Corovax and the government’s perceived indifference to victims of the public health response to SPARS. One senior health official argued that time and a robust medical monitoring program for vaccine recipients—the components of which were already in place—should be sufficient to determine whether public concern about long-term effects was, in fact, warranted: “We have to wait for the data. People need to understand that fact.”
"YOU CAN'T MAKE THIS $H!T UP"
Nancy Pelosi about Obama Care….
We will have to wait to see what’s in it.